Iptacopan is an oral, investigational inhibitor of factor B, a key component of the proximal alternative pathway of the complement system.
Compound(s) are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established and there is no guarantee that they will become commercially available for the use(s) under investigation.
MOA data are based on in vitro/in vivo data.
Factor B small-molecule inhibitor